BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, December 31, 2025
Home » Authors » Mark McCarty

Mark McCarty

Articles

ARTICLES

Washington roundup: FDA touts improvements in leaner device review process

Nov. 29, 2012
By Mark McCarty

Washington roundup: Firm warned for using 'FDA-cleared' in product brochure

Nov. 28, 2012
By Mark McCarty

Washington roundup: FDA seeks input on limits for custom medical devices

Nov. 27, 2012
By Mark McCarty

Washington roundup: FDA releases long-awaited artificial pancreas guidance

Nov. 26, 2012
By Mark McCarty

Washington roundup: CMS eyes focused approach to bundling for 2013 doc fees

Nov. 19, 2012
By Mark McCarty

Washington roundup: FDA inks draft guidance for multiplexed nucleic acid tests

Nov. 16, 2012
By Mark McCarty

Washington roundup: Nexon: Failure 'not an option' for medical device tax repeal

Nov. 15, 2012
By Mark McCarty

Device taxes, fiscal cliffs, and the Petraeus-Benghazi imbroglio

Nov. 14, 2012
By Mark McCarty
New York may be the town that never sleeps, but Washington is the town that never fails to amaze. We currently have a sex scandal seeming to rival the Bill Clinton-Monica Lewinsky detonation, but the current scandal has more in common with the Profumo affair because a secretary of defense was involved. Obviously the President has a number of distractions. One of those is Benghazi, a story seeming to grow more convoluted every day. Somewhat linked to all that – more or less immediately – are Gen. David...
Read More

Washington roundup: FDA finds several problems with Integra's CAPA system

Nov. 14, 2012
By Mark McCarty

Washington roundup: Decision support tools for EP devices seen as of 'low quality'

Nov. 13, 2012
By Mark McCarty
The Agency for Healthcare Research and Quality (AHRQ) posted a technology report on decision support tools for cardiac electrophysiology devices, but the effort yielded little evidentiary fruit to support the evaluation. The dearth of data suggests the impact of these tools on clinical decision-making could combine with cost pressures to suppress use of pacemakers and implantable cardioverter defibrillators in patients who are legitimate candidates. However, informed consent issues and questions of device de-activation are likewise conspicuous in the report, leaving researchers with a large set of poorly described variables to be explored in future studies.
Read More
View All Articles by Mark McCarty

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 31, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 31, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Businessman, businesswoman handshake

    Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

    BioWorld
    Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
  • Asia focused map inside light bulb

    Big pharma taps fast Asia innovation in search of next Keytruda

    BioWorld
    Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing